X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA BIOCON LTD ALEMBIC PHARMA/
BIOCON LTD
 
P/E (TTM) x 29.0 82.9 35.0% View Chart
P/BV x 6.6 7.8 84.8% View Chart
Dividend Yield % 0.7 0.2 447.7%  

Financials

 ALEMBIC PHARMA   BIOCON LTD
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
BIOCON LTD
Mar-17
ALEMBIC PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs7921,162 68.1%   
Low Rs443483 91.8%   
Sales per share (Unadj.) Rs167.0194.6 85.8%  
Earnings per share (Unadj.) Rs38.234.4 110.9%  
Cash flow per share (Unadj.) Rs42.048.3 87.0%  
Dividends per share (Unadj.) Rs4.001.00 400.0%  
Dividend yield (eoy) %0.60.1 532.7%  
Book value per share (Unadj.) Rs84.9241.9 35.1%  
Shares outstanding (eoy) m188.52200.00 94.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.74.2 87.5%   
Avg P/E ratio x16.223.9 67.7%  
P/CF ratio (eoy) x14.717.0 86.3%  
Price / Book Value ratio x7.33.4 213.9%  
Dividend payout %10.52.9 360.6%   
Avg Mkt Cap Rs m116,383164,440 70.8%   
No. of employees `000NA9.2 0.0%   
Total wages/salary Rs m4,2147,470 56.4%   
Avg. sales/employee Rs ThNM4,213.9-  
Avg. wages/employee Rs ThNM809.0-  
Avg. net profit/employee Rs ThNM745.2-  
INCOME DATA
Net Sales Rs m31,48738,911 80.9%  
Other income Rs m551,571 3.5%   
Total revenues Rs m31,54240,482 77.9%   
Gross profit Rs m10,0609,795 102.7%  
Depreciation Rs m7222,772 26.0%   
Interest Rs m37260 14.2%   
Profit before tax Rs m9,3568,334 112.3%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1601,616 133.7%   
Profit after tax Rs m7,1946,881 104.6%  
Gross profit margin %31.925.2 126.9%  
Effective tax rate %23.119.4 119.1%   
Net profit margin %22.817.7 129.2%  
BALANCE SHEET DATA
Current assets Rs m15,06640,477 37.2%   
Current liabilities Rs m7,67416,783 45.7%   
Net working cap to sales %23.560.9 38.5%  
Current ratio x2.02.4 81.4%  
Inventory Days Days6760 112.3%  
Debtors Days Days4183 49.0%  
Net fixed assets Rs m8,23745,073 18.3%   
Share capital Rs m3771,000 37.7%   
"Free" reserves Rs m15,41647,377 32.5%   
Net worth Rs m16,00548,377 33.1%   
Long term debt Rs m021,082 0.0%   
Total assets Rs m24,59493,942 26.2%  
Interest coverage x255.233.1 772.2%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.30.4 309.1%   
Return on assets %29.47.6 386.8%  
Return on equity %44.914.2 316.0%  
Return on capital %58.712.6 465.4%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Exports (fob) Rs m17,551NA-   
Imports (cif) Rs m3,283NA-   
Fx inflow Rs m17,81112,988 137.1%   
Fx outflow Rs m5,3187,899 67.3%   
Net fx Rs m12,4935,089 245.5%   
CASH FLOW
From Operations Rs m9,3046,400 145.4%  
From Investments Rs m-3,105-4,985 62.3%  
From Financial Activity Rs m-1,959-1,775 110.4%  
Net Cashflow Rs m4,240-473 -896.4%  

Share Holding

Indian Promoters % 74.1 40.4 183.4%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 2.9 8.4 34.5%  
FIIs % 9.1 10.7 85.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 19.9 69.8%  
Shareholders   49,328 109,995 44.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFE  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS